A new wave of drugs targeting non-alcoholic steatohepatitis — now increasingly called metabolic dysfunction-associated steatohepatitis, or MASH — is clearing critical clinical trial milestones, offering real hope to the estimated 6 to 8 million Americans living with this progressive liver disease. Among the most notable recent advances, Altimmune’s pemvidutide, a dual glucagon/GLP-1 receptor agonist, received FDA Breakthrough Therapy Designation on January 5, 2026, following Phase 2b trial data showing statistically significant improvements in fibrosis markers. This designation puts pemvidutide on an accelerated regulatory path and signals the FDA’s recognition that the drug may offer a substantial improvement over existing treatments for a condition that, left unchecked, can lead to cirrhosis, liver failure, and heightened dementia risk. For those following the intersection of liver health and brain health, these developments matter more than they might first appear.
NASH/MASH is not merely a liver disease — chronic liver inflammation and metabolic dysfunction have been linked in a growing body of research to cognitive decline, vascular dementia, and Alzheimer’s disease risk. A liver that cannot properly clear toxins and manage metabolism places the brain under sustained, low-grade assault. The progress in NASH drug development over the past two years, from the first-ever FDA approval in March 2024 to a robust pipeline of candidates now entering Phase 3 trials, represents a meaningful shift for patients and caregivers who understand that protecting the liver is part of protecting the brain. This article covers the drugs that have already been approved, the candidates crossing major trial hurdles right now, the specific data behind each, and what all of it means for patients and families navigating dementia risk in the context of metabolic liver disease.
Table of Contents
- What New Drugs for Non-Alcoholic Steatohepatitis Have Crossed Major Trial Hurdles?
- How NASH Drug Approvals Compare — And Where They Fall Short
- Pemvidutide, Lanifibranor, and Efruxifermin — The Next Wave of NASH Treatments
- What NASH Treatment Means for Dementia Risk and Brain Health
- Limitations of Current NASH Treatments and Common Pitfalls
- AI and Regulatory Innovation Accelerating NASH Drug Development
- What Comes Next for NASH Treatment and Brain Health
- Conclusion
- Frequently Asked Questions
What New Drugs for Non-Alcoholic Steatohepatitis Have Crossed Major Trial Hurdles?
The NASH treatment landscape has gone from zero approved drugs to two in the span of roughly 18 months, with several more candidates generating Phase 2 and Phase 3 data that would have been difficult to imagine a decade ago. Resmetirom, marketed as Rezdiffra by Madrigal Pharmaceuticals, became the first-ever FDA-approved drug for NASH in March 2024, granted accelerated approval for adults with noncirrhotic NASH and moderate-to-advanced liver fibrosis at stages F2 through F3. In clinical trials, NASH resolution occurred in 26 to 30 percent of patients compared to 10 percent on placebo, and fibrosis improvement was seen in 24 to 26 percent versus 14 percent on placebo. Resmetirom works as an oral, liver-directed thyroid hormone receptor-beta agonist — essentially nudging the liver’s own metabolic machinery to reduce fat accumulation and inflammation. Then, in August 2025, the FDA approved semaglutide — already well known under the brand name Wegovy for weight management — for MASH with moderate-to-advanced fibrosis, making it the first GLP-1 receptor agonist approved for this indication and only the second MASH drug ever. The Phase 3 ESSENCE trial, published in the New England Journal of Medicine, enrolled 1,197 patients and showed MASH resolution in 62.9 percent of those receiving semaglutide 2.4 mg weekly versus 34.3 percent on placebo.
Fibrosis reduction occurred in 36.8 percent versus 22.4 percent on placebo. These numbers represent a substantial leap over resmetirom’s results, though direct head-to-head comparisons have not been conducted and the two drugs work through entirely different mechanisms. Beyond these approvals, the drug crossing the most notable trial hurdle in early 2026 is pemvidutide, Altimmune’s balanced 1:1 glucagon/GLP-1 dual receptor agonist. Its Phase 2b IMPACT trial reported 48-week topline data in December 2025, demonstrating statistically significant improvements in fibrosis markers: Enhanced Liver Fibrosis scores dropped by 0.49 and 0.58 points in the treatment arms versus a 0.16-point increase on placebo, with p-values below 0.0001. Liver stiffness measurements fell by 3.04 and 3.97 kPa versus just 0.03 on placebo. Weight loss of 5.0 to 6.2 percent at 24 weeks compared to 1.0 percent on placebo adds metabolic benefit. Altimmune plans to initiate Phase 3 trials in 2026.
How NASH Drug Approvals Compare — And Where They Fall Short
The two approved NASH drugs offer genuinely different profiles, and understanding their tradeoffs matters for patients and clinicians weighing options. Resmetirom is an oral daily pill that targets the liver directly through thyroid hormone receptor-beta activation. Its NASH resolution rates of 26 to 30 percent are meaningful but modest, and its wholesale price of $47,400 per year raises serious access questions, particularly for patients on Medicare or those without robust prescription coverage. For families already stretched thin by the costs of dementia caregiving, adding a nearly fifty-thousand-dollar annual prescription is not a trivial consideration. Semaglutide, by contrast, is a weekly subcutaneous injection with NASH resolution rates more than double those of resmetirom — 62.9 percent versus roughly 28 percent. It also carries the additional benefit of significant weight loss, which is independently valuable for metabolic health and has its own emerging links to reduced dementia risk.
However, semaglutide is not without limitations. Gastrointestinal side effects including nausea, vomiting, and diarrhea are common, particularly during dose escalation. It also requires injection, which some patients find burdensome. And critically, neither drug has yet demonstrated that it prevents progression to cirrhosis or reduces liver-related mortality in long-term outcomes data — both were approved on the basis of improvements in histological markers like fibrosis stage and NASH resolution on biopsy, which are surrogate endpoints. The practical reality is that if you or a family member has been diagnosed with NASH at fibrosis stage F2 or F3, there are now two FDA-approved options where there were none before March 2024. But if the disease has already progressed to compensated cirrhosis (F4), neither approved drug currently carries that indication, and treatment options remain far more limited. This is precisely why the pipeline drugs matter so much.
Pemvidutide, Lanifibranor, and Efruxifermin — The Next Wave of NASH Treatments
The pipeline behind the two approved drugs is broader and more diverse in mechanism than many patients realize. Pemvidutide’s Breakthrough Therapy Designation from the FDA, granted January 5, 2026, is significant because it provides Altimmune with more intensive FDA guidance, rolling review eligibility, and potentially faster approval. The drug’s dual agonism — hitting both glucagon and GLP-1 receptors in a balanced 1:1 ratio — is designed to attack both the metabolic and fibrotic components of MASH simultaneously. Its Phase 2b IMPACT trial data showed not just fibrosis marker improvement but also clinically relevant weight loss, suggesting it could address the systemic metabolic dysfunction that underlies both liver and brain health deterioration. Lanifibranor, developed by Inventiva, takes yet another approach as a pan-PPAR agonist, activating all three peroxisome proliferator-activated receptor subtypes. Its Phase 3 NATiV3 trial completed enrollment of 1,009 patients with F2 and F3 fibrosis, as announced in April 2025, testing daily doses of 800 mg and 1,200 mg.
A blinded interim analysis showed improvements in liver function, metabolism, and fibrosis markers, with topline results expected in the second half of 2026. Lanifibranor is notable for its oral dosing and its broad metabolic mechanism, though the full safety profile at the higher 1,200 mg dose remains to be characterized in the Phase 3 readout. Efruxifermin, from Akero Therapeutics, is an FGF21 analog — fibroblast growth factor 21 is a hormone involved in regulating metabolism, insulin sensitivity, and lipid handling. It is currently being evaluated in three Phase 3 trials under the SYNCHRONY program: Histology, Real-World, and Outcomes. Results from the SYNCHRONY Real-World trial are expected in the first half of 2026. What sets efruxifermin apart is that it is the only drug currently being assessed for MASH in both pre-cirrhotic and cirrhotic stages, meaning it could eventually fill the treatment gap that exists for patients with more advanced disease. Its Phase 2b HARMONY trial demonstrated significant fibrosis improvement over 96 weeks, a longer treatment duration than most competing trials have tested.
What NASH Treatment Means for Dementia Risk and Brain Health
The connection between liver disease and cognitive decline is not speculative — it is grounded in shared pathophysiology. The liver clears ammonia, manages cholesterol metabolism, regulates systemic inflammation, and processes the very lipids that form the structural basis of brain cell membranes. When NASH causes the liver to become inflamed and fibrotic, these functions degrade. Hyperammonemia from liver dysfunction can cause hepatic encephalopathy, a well-documented cause of confusion, impaired attention, and cognitive impairment that is sometimes misdiagnosed as early dementia. Even subclinical hepatic encephalopathy — below the threshold of obvious symptoms — has been associated with measurable cognitive deficits on neuropsychological testing. Beyond the direct toxin-clearance pathway, NASH shares its core metabolic drivers with dementia risk factors: insulin resistance, systemic inflammation, dyslipidemia, and obesity.
These are not coincidental overlaps. Insulin resistance in the brain — sometimes called “type 3 diabetes” in Alzheimer’s research — impairs neuronal glucose uptake and accelerates amyloid plaque formation. A drug like semaglutide that improves NASH resolution while also reducing weight, improving insulin sensitivity, and lowering systemic inflammation may be addressing dementia risk through multiple simultaneous channels, though this has not yet been proven in dedicated neurocognitive outcome trials. The tradeoff for families to consider is this: NASH drugs are expensive, require long-term adherence, and carry their own side effects. But untreated NASH that progresses to cirrhosis creates a cascade of metabolic and neurological consequences that are far harder and costlier to manage. For individuals with both NASH and early cognitive symptoms, or those with a family history of dementia and metabolic syndrome, discussing liver health screening with a hepatologist is a concrete, actionable step that many dementia care plans currently overlook.
Limitations of Current NASH Treatments and Common Pitfalls
No discussion of these drugs is honest without acknowledging what they cannot yet do. Both resmetirom and semaglutide were approved through the FDA’s accelerated approval pathway, which means their approval is based on surrogate endpoints — histological changes on liver biopsy — rather than on demonstrated reductions in cirrhosis progression, liver transplant, or death. Confirmatory trials are required, and if those trials fail to show clinical benefit, the approvals could theoretically be withdrawn. This has happened before with other accelerated approvals in different disease areas, so patients should understand that the evidence base, while promising, is not yet definitive on the outcomes that matter most. Access is another significant barrier. Resmetirom’s $47,400 annual wholesale price and semaglutide’s cost — already a source of national debate in its weight-loss indication — put these drugs out of reach for many patients without favorable insurance coverage.
Prior authorization requirements, step therapy protocols, and formulary restrictions add further delays. For patients already managing the financial burden of dementia care for a spouse or parent, the additional cost of a NASH drug can feel insurmountable. Patient assistance programs exist but are not universally available, and navigating them requires advocacy and persistence. A warning that clinicians and caregivers should heed: NASH is frequently asymptomatic until it reaches advanced stages. Liver enzymes can be normal even in the presence of significant fibrosis. Relying on routine blood work alone to screen for NASH is insufficient. Non-invasive tools like FibroScan (vibration-controlled transient elastography) and blood-based fibrosis scores like FIB-4 are increasingly available and should be part of metabolic health screening, particularly for patients with type 2 diabetes, obesity, or metabolic syndrome — populations that overlap heavily with those at elevated dementia risk.
AI and Regulatory Innovation Accelerating NASH Drug Development
One development from March 2026 that received less attention but carries long-term significance is the FDA’s qualification of AIM-NASH, the first AI-based tool approved for scoring liver biopsies in MASH clinical trials. Liver biopsy reading has historically been subjective — pathologists can disagree on fibrosis staging and inflammation grading, introducing variability that muddies clinical trial results. AIM-NASH standardizes this process using artificial intelligence and can now be used in any MASH drug development program and regulatory filing. For drug developers, this means cleaner data, faster trial readouts, and potentially smaller required sample sizes.
For patients, it means that the next generation of NASH drugs may reach the market faster and with stronger evidence behind them. Separately, Vimgreen Pharmaceuticals received IND approval from China’s Center for Drug Evaluation for VG081821, the first A2A receptor antagonist cleared globally for NASH clinical investigation, with a Phase IIa trial planned for the second half of 2026. And denifanstat received FDA Breakthrough Therapy Designation for non-cirrhotic NASH with moderate-to-advanced fibrosis, with a Phase 3 trial scheduled to begin. These developments underscore that the NASH pipeline is not narrowing — it is diversifying across mechanisms, geographies, and regulatory pathways.
What Comes Next for NASH Treatment and Brain Health
The second half of 2026 will be pivotal. Topline results from lanifibranor’s Phase 3 NATiV3 trial and efruxifermin’s SYNCHRONY Real-World trial are both expected, and Altimmune plans to launch pemvidutide’s Phase 3 program. If even one of these candidates demonstrates clear fibrosis improvement and acceptable safety, patients could have a third approved option by 2027 or 2028 — and potentially the first drug approved for cirrhotic MASH, if efruxifermin’s data holds in that population.
For dementia caregivers and those managing their own brain health, the practical takeaway is not to wait for the perfect drug. The metabolic damage that NASH causes to both liver and brain is cumulative and, at some point, irreversible. Screening for NASH now, discussing existing approved treatments with a hepatologist, and addressing modifiable risk factors like diet, physical activity, and insulin resistance are steps that can be taken today. The drug pipeline is more promising than it has ever been, but the best outcomes will belong to those who catch the disease early — before fibrosis advances and before its downstream effects on cognition become entrenched.
Conclusion
The NASH treatment landscape has undergone a transformation that would have seemed improbable just three years ago. From zero approved drugs to two — resmetirom and semaglutide — with a deep pipeline including pemvidutide, lanifibranor, and efruxifermin all crossing major trial hurdles, patients now have options and genuine reasons for cautious optimism. The FDA’s willingness to grant Breakthrough Therapy Designations and to qualify AI-based diagnostic tools signals that the regulatory environment is aligned with the urgency of the disease. For readers of this site, the message is twofold.
First, NASH is a liver disease with direct and indirect consequences for brain health, and it deserves a place in any comprehensive dementia prevention or care strategy. Second, the drugs now available and those in late-stage development represent tools that can interrupt the metabolic cascade linking liver inflammation to cognitive decline. Talk to a hepatologist. Ask about non-invasive fibrosis screening. And stay informed as the Phase 3 readouts arrive later this year — the data will matter not just for liver outcomes, but for the brain health of millions.
Frequently Asked Questions
What is the difference between NASH and MASH?
They refer to the same condition. NASH (non-alcoholic steatohepatitis) was renamed MASH (metabolic dysfunction-associated steatohepatitis) in 2023 to better reflect that the disease is driven by metabolic dysfunction rather than simply the absence of alcohol use. Both terms are still used in clinical and regulatory settings.
Is there a pill for NASH, or do all treatments require injections?
Resmetirom (Rezdiffra) is an oral daily pill. Semaglutide (Wegovy) requires a weekly subcutaneous injection. Among pipeline drugs, lanifibranor is also oral, while pemvidutide and efruxifermin are injectable. So patients do have oral options, though the most effective approved treatment by resolution rates — semaglutide — currently requires injection.
Can NASH drugs reduce dementia risk?
No NASH drug has been proven in a dedicated trial to reduce dementia risk. However, by improving insulin resistance, reducing systemic inflammation, and preventing liver-related toxin buildup, effective NASH treatment addresses several established dementia risk factors. Semaglutide in particular is being studied separately for potential neuroprotective effects, but definitive evidence is not yet available.
How do I know if I have NASH if I have no symptoms?
Most people with NASH have no symptoms until the disease is advanced. Standard liver enzyme blood tests can miss it. Ask your doctor about a FIB-4 score (calculated from routine blood work) or a FibroScan, a non-invasive imaging test that measures liver stiffness. These are especially important if you have type 2 diabetes, obesity, or metabolic syndrome.
How much do approved NASH drugs cost?
Resmetirom has a wholesale price of approximately $47,400 per year. Semaglutide’s cost varies but is also substantial, particularly given ongoing national debates about GLP-1 drug pricing. Insurance coverage, prior authorization requirements, and patient assistance programs all affect out-of-pocket costs and vary significantly by plan and region.
Should someone with dementia be screened for NASH?
There is a reasonable clinical argument for screening dementia patients — especially those with metabolic syndrome, type 2 diabetes, or obesity — for NASH, since untreated liver disease can worsen cognitive symptoms through hepatic encephalopathy and systemic inflammation. Discuss this with both the patient’s neurologist and a hepatologist to determine whether screening and treatment are appropriate given the individual’s overall care goals.
